BACKGROUND The worldwide prevalence of inflammatory bowel disease (IBD) continues to rise, motivating extensive exploration into possible contributing factors. Proton pump inhibitors (PPIs) are frequently prescribed medications for managing various gastrointestinal disorders. However, uncertainties persist regarding the implications of chronic PPI therapy and its potential association with the onset of IBD. AIM To assess the association between PPI use and incident IBD risk via a systematic revi